Asthma therapy from the practice perspective: Changes in the wind

Journal of Clinical Pharmacology

Volumn 39, Issue 3, 1999, Pages 223-229

  Pierce, Charles H ^a  

^a MDS Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; AMINOPHYLLINE; ANTIHISTAMINIC AGENT; BAMBUTEROL; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DEXAMETHASONE; FLUTICASONE; FLUTICASONE PROPIONATE; FORMOTEROL; FORMOTEROL FUMARATE; IBUDILAST; IPRATROPIUM BROMIDE; ISOPRENALINE; KETOTIFEN; KETOTIFEN FUMARATE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHYLXANTHINE DERIVATIVE; MONTELUKAST; MOXASTINE TEOCLATE; NEDOCROMIL SODIUM; NEDODROMIL; NONSTEROID ANTIINFLAMMATORY AGENT; PRANLUKAST; PYRANOQUINOLINE; SALBUTAMOL; TERBUTALINE; THEOPHYLLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZAFIRLUKAST; ZILEUTON;

ANTICHOLINERGIC EFFECT; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRONCHOSPASM; CLINICAL PROTOCOL; CONFERENCE PAPER; CYTOKINE RELEASE; GOOD CLINICAL PRACTICE; HEALTH CARE COST; LUNG FUNCTION TEST; MEDICAL PRACTICE; METERED DOSE INHALER; PATIENT EDUCATION; PEAK EXPIRATORY FLOW; PRACTICE GUIDELINE; PREVALENCE; PRIMARY MEDICAL CARE; TREATMENT PLANNING;

ANTI-ASTHMATIC AGENTS; ASTHMA; HUMANS; PHYSICIAN'S ROLE; PRACTICE GUIDELINES;

EID: 0032979460     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (43)

1. National Center for Health Statistics: National Health Interview Survey, 1994, DHHS Pub. No. (PHS) 95-1521 (Hyattsville, MD: National Center for Health Statistics, 1995).
2. National Asthma Education and Prevention Program (National Heart, Lung, and Blood Institute): Guidelines for the Diagnosis and Management of Asthma, Pub. No. 97-4051, Second Expert Panel on the Management of Asthma (Bethesda, MD: National Institutes of Health, 1997).
3. Horwitz RJ, Busse WW: Inflammation and asthma. Clin Chest Med 1995;16:583-620.
4. Lazarus SC: Inflammation, inflammatory mediators, and mediator antagonists in asthma. J Clin Pharmacol 1998;38:577-582.
5. Kay AB: Asthma and inflammation. J Allergy Clin Immunol 1991;87:893-911.
6. Haley KJ, Drazen JM: Inflammation and airway function in asthma: what you see is not necessarily what you get. Am J Respir Crit Care Med 1998;157:1-3.
7. Townley RG: Adrenergic receptors, mechanisms, and the late allergic reaction. In, Townley RG, Agrawal DK (eds.): Immunopharmacology of Allergic Disease. New York: Marcel Dekker, Inc. 1996;491-522.
8. Drazen JM, Ann JP, Austen KF: Sorting out the cytokines of asthma. J Exp Med 1996;183:1-5.
9. Nadel JA, Busse WW: Asthma. Am J Respir Crit Care Med 1998;157:S130-S138.
10. Weiss KB, Gergen PJ, Hodgson TA: An economic evaluation of asthma in the United States. N Eng J Med 1992;326:862-866.
11. Page C: Theophylline as an anti-inflammatory agent. Eur Resp Rev 1996;6(34):74-78.
12. Barnes N: Leukotriene receptor antagonists. J Roy Soc Med 90:200-203.
13. O'Byrne PM, Isreal E, Drazen JM: Antileukotrienes in the treatment of asthma. Ann Int Med 1997;127:472-480.
14. 2-agonists and the risk of death and near death from asthma. N Engl J Med 1992;326:501-506.
15. Hemstreet MPB: Atropine nebulization: simple and safe. Ann Allergy 1980;44:138-141.
16. Beakes DE: The use of anticholinergics in asthma. J Asthma 1997;34(5):357-368.
17. Barnes PJ: The role of theophylline in severe asthma. Eur Respir Rev 1996;6(34):88-92.
18. DuBuske LM: Asthma: diagnosis and management of nocturnal symptoms. Comprehensive Therapy 1994;20(11):628-639.
19. Kamada A, Szefler SJ, Martin RJ, Boushey HA, Chinchilli RM, Drazen JM, Fish JE, Israel E, Lazarus SC, Lemanske RF: Issues in the use of inhaled corticosteroids. Am J Respir Crit Care Med 1996;153:1739-1748.
20. Kelly HW: Comparison of inhaled corticosteroids. Ann Pharmacotherapeutics 1998;32(6):220-232.
21. Gross KM, Ponte CD: New strategies in the medical management of asthma. American Family Physician 1998;58:89-100.
22. Parnham MJ: Sodium cromoglycate and nedocromil sodium in the therapy of asthma: a critical comparison. Pulm Pharmacol 1996;9(2):95-105.
23. Hay WP: Pharmacology of leukotriene receptor antagonists: more than inhibitors of bronchoconstriction. Chest 1997;111(2):355-455.
24. Noonan MJ, Chervinsky P, Brandon M, Zhang J, Kundu S, McBurney J, Reiss TF: Montelukast: a potent leukotriene receptor antagonist, causes dose related improvements in chronic asthma. Eur Respir J 1998;11:1232-1239.
25. Drazen JM: Pharmacology of leukotriene receptor antagonists and 5 lipoxygenase inhibitors in the management of asthma. Pharmacotherapy 1997;17(Suppl.):225-295.
26. Ohashi M, Nishino K: Effect of Ibudilast, a novel antiasthmatic agent on anaphylactic bronchocontriction: predominant involvement of endogenous slow reacting substance of anaphylaxis. Int Archc Allergy Immunol 1993;101(3):288-296.
27. Hoshino M et al: Effects of ketotifin on symptoms and on bronchial mucosa in patients with atopic asthma. Allergy 1997;52(8): 814-820.
28. Asthma: current trends, research developments and commercial opportunities. In, Scrip Reports (Richmond, UK: PJB Publications, 1996).
29. Kleerup EC: Bronchodilators: new drugs and controversies. Current Opinions in Pulm Medicine 1997;3:17-22.
30. Floreani AA, Rennard SI: Experimental treatments for asthma. Current Opinion in Pulm Med 1997;3:30-41.
31. Torphy TJ: Phosphodiesterase isozymes, molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 1998;157:351-370.
32. Ford-Hutchinson AW: FLAP: a novel drug target for inhibiting the synthesis of leukotrienes. Trends in Pharmacol Sci 1991;12(2):68-70.
33. Adcock IM, Matthews JG: New drugs for asthma. DDT 1998;3(9):395-399.
34. Singh AD, Sanderson CJ: Anti-interleukin 5 strategies as a potential treatment for asthma. Thorax 1997;52:483-485.
35. Hosford D et al: Platelet-activating factor (PAF) and PAF antagonists in asthma. Crit Rev Ther Drug Carrier Syst 1990;7(3):261-273.
36. Kurosawa M: Role of thromboxane A2 synthetase inhibitors in the treatment of patients with bronchial asthma. Clin Ther 1995;17(1):2-11.
37. Clark JM, Moore WR, Tanaka RD: Tryptase inhibitors: a new class of anti-inflammatory drugs. Drugs of the Future 1996;21:811-816.
38. Morley J: Potassium channel openers and asthma. Clin Rev Altergy 1994;12(1):109-120.
39. Bosse CG, Criner GJ: Using spirometry in the primary care office: a guide to technic and interpretation of results. Postgrad Med 1997;93(5):122-148.
40. Wanger J: Office spirometry: equipment selection and raining of staff in the private practice setting. J Asthma 1997;34(2):93-104.
41. O'Callaghan C: Delivery systems: the science. Pediatr Pulmonol 1997;15(Suppl.):51-54.
42. Tashkin DP: New devices for asthma. J Allergy Clin Immunol 1998;101(2, Pt. 2):S409-S416.
43. Horwitz RJ, McGill KA, Busse WW: The role of leukotriene modifiers in the treatment of asthma. Am J Respir Crit Care Med 1998;157:1363-1371.